


## PHARMACEUTICAL 2022


## LUMOS PHARMA INC. Rank 186 of 475







## PHARMACEUTICAL 2022





The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 211% points. The greatest weakness of LUMOS PHARMA INC. is the variable Net Income, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is -46%, being 230% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	99,677
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,130
Liabilities, Non-Current	6,205
Other Assets	556
Other Compr. Net Income	0
Other Expenses	-636
Other Liabilities	0
Other Net Income	281
Property and Equipment	79
Research and Development	16,246
Revenues	230
Selling, General and Administrative Expense	15,331

Output Variable	Value in 1000 USD
Assets	100,312
Liabilities	11,335
Expenses	30,941
Stockholders Equity	88,977
Net Income	-30,430
Comprehensive Net Income	-30,430
Economic Capital Ratio	-46%

